The FDA is scheduled to decide whether or not to approve Eton Pharmaceuticals Inc.’s (ETON) Alkindi Sprinkle, a taste neutral granule formulation of hydrocortisone, on September 29, 2020.Alkindi Sprinkle is proposed as a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in infants to patients less than 17 years of age. Eton acquired U.S. marketing rights to Alkindi Sprinkle from Diurnal Group plc (DNL).If approved, Alkindi Sprinkle would be the first Adrenal Insufficiency replacement therapy specifically designed and developed for children in the U.S.Eton believes the market opportunity for Alkindi Sprinkle in the United States is greater than $100 million annually.The product was approved in Europe in 2018 under the trade name Alkindi and is marketed by Diurnal in select countries throughout Europe. ETON closed Wednesday’s (Aug.26, 2020) trading at $6.73, down 2.89%.